al b. benson iii, md, facp professor of medicine associate director for clinical investigations...
TRANSCRIPT
![Page 1: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/1.jpg)
Al B. Benson III, MD, FACPProfessor of MedicineAssociate Director for Clinical InvestigationsRobert H. Lurie Comprehensive Cancer Centerof Northwestern University
To Treat or Not to Treat Stage II Colon Cancer = Yes (sometimes)
![Page 2: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/2.jpg)
Disclosures
Research = Genentech, Amgen, Astellas, Gilead, Bayer, Novartis
Consultant = Sanofi, Bayer, Genentech, Lilly/ImClone, Bristol-Myers Squibb
Genomic Health (Uncompensated)
![Page 3: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/3.jpg)
![Page 4: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/4.jpg)
![Page 5: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/5.jpg)
![Page 6: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/6.jpg)
The Stage II Colon Cancer Controversies/Dilemmas
Imperfect risk factors/assessments are not linked to
treatment efficiency
Growing list of risk factors and tools to define risk
Overall good prognosis but subsets clearly recur
![Page 7: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/7.jpg)
The Stage II Colon Cancer Controversies/Dilemmas
Proof of principle: chemotherapy reduces risk but for
whom?
Choice extrapolated from Stage III benefits – is this
correct?
Role of oxaliplatin: Stage T4, MSI-H
![Page 8: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/8.jpg)
The Stage II Colon Cancer Controversies/Dilemmas
Complicated discussion with patients
Patient perceptions of risk (and MD’s)
Cannot predict absolute risk for individual
Cannot link risk and treatment benefit
Cannot define which factors are most important
![Page 9: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/9.jpg)
AJCC v7
Gunderson et al, JCO 2009
Stage II Stage III
![Page 10: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/10.jpg)
QUASAR: 5FU/LV Chemotherapy Benefit in the 1,436 Evaluable Stage II Colon Cancer Patients
RFI
Treatment Surgery Chemo
Pro
port
ion
Eve
nt F
ree
0.0
0.2
0.4
0.6
0.8
1.0
Years
0 1 2 3 4 5
OS
Treatment Surgery Chemo
Pro
port
ion
Eve
nt F
ree
0.0
0.2
0.4
0.6
0.8
1.0
Years
0 1 2 3 4 5
DFS
Treatment Surgery Chemo
Pro
port
ion
Eve
nt F
ree
0.0
0.2
0.4
0.6
0.8
1.0
Years
0 1 2 3 4 5
Kerr et al., ASCO 2009, #4000
RFI (recurrence-free interval) DFS (disease-free survival)
OS (Overall Survival)
![Page 11: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/11.jpg)
Kaplan-Meier estimates of disease-free survival (A) by treatment arm and (B) by treatment arm and by stage
(intent-to-treat population).
André T et al. JCO 2009;27:3109-3116
©2009 by American Society of Clinical Oncology
![Page 12: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/12.jpg)
Kaplan-Meier estimates of overall survival (A) by treatment arm and (B) by treatment arm and by stage
(intent-to-treat population).
André T et al. JCO 2009;27:3109-3116
©2009 by American Society of Clinical Oncology
![Page 13: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/13.jpg)
Rates of (A) disease-free, (B) relapse-free, (C) overall, and (D) post–disease-free survival in patients with high-risk stage II colon cancer
treated with leucovorin and fluorouracil with oxaliplatin (FOLFOX4) or without (FL).
Tournigand C et al. JCO 2012;30:3353-3360
©2012 by American Society of Clinical Oncology
![Page 14: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/14.jpg)
Oxaliplatin trials with censoring analyses of different time points.
McCleary N J et al. JCO 2013;31:2600-2606
©2013 by American Society of Clinical Oncology
![Page 15: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/15.jpg)
Recurrence RiskBowel obstruction or perforationT-Stage# of nodes assessedTumor gradeLymphatic/vascular invasionMargin status
Treatment Benefit None
* NCCN Clinical Practice Guidelines for Oncology: Colon Cancer v3.2009 ASCO Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer, JCO, 2004.
![Page 16: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/16.jpg)
Numeracy calculator www.adjuvantonline.com: · three choices for lymph nodes (none, 1–4, 5+ lymph nodes),· three choices for tumor stage (T1/T2, T3, T4),· two choices for grade (low, high),· four choices for age (49 years or younger, 50–59, 60–69, 70 or older). Adjuvant! tool www.mayoclinic.com/calcs has three additional options:gender (male, female), comorbidity (perfect health, minor problems, average for age, or major problems), and the number of examined lymph nodes (0, 1–3, 4–10, >10).
![Page 17: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/17.jpg)
Overall survival by stage group (Kaplan-Meier).
O'Connor E S et al. JCO 2011;29:3381-3388
©2011 by American Society of Clinical Oncology
![Page 18: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/18.jpg)
Similar Coexpression of 48 Recurrence Risk Genes Stage II vs Stage III Colon Cancer
Stage II Stage III
UMPSMYBL2CSEL1CMYCNME1HNRPDSKP2RRM1MCM2RRM2KI_67CDC20P16_INK4P14ARFKLK6GRB10TGFBILAMC2P21CDC42BPAHSPA1AS100A4
OPN__OSTEOPONTINPAI1GADD45BEGR1STMY3DLC1IGFBP3SFRP4PDGFCIGFBP7CALD1TIMP3TGFB3SFRP2INHBAFAPCTHRC1LOXL2SPARCCOL1A1BGNTIMP2ANTXR1ITGB1AKT3AKAP12
Average Distance Between Clusters
0.0 0.2 0.4 0.6 0.8 1.0 1.2
HNRPDUMPSNME1MYBL2CSEL1CMYCSKP2RRM1MCM2RRM2KI_67CDC20P16_INK4P14ARFGRB10HSPA1ASTMY3LAMC2S100A4KLK6TGFBIP21CDC42BPA
OPN__OSTEOPONTINPAI1GADD45BEGR1IGFBP3IGFBP7TIMP3LOXL2SFRP4PDGFCTGFB3SFRP2INHBACTHRC1FAPSPARCCOL1A1BGNTIMP2ANTXR1ITGB1DLC1CALD1AKT3AKAP12
Average Distance Between Clusters
0.0 0.2 0.4 0.6 0.8 1.0 1.2
Stromal Genes
Cell CycleGenes
![Page 19: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/19.jpg)
p=0.004
0%
5%
10%
15%
20%
25%
30%
35%
0 10 20 30 40 50 60 70
Recurrence Score
Ris
k o
f re
cu
rre
nc
e a
t 3
ye
ars
QUASAR RESULTS: Colon Cancer Recurrence Score Predicts Recurrence Following Surgery
STROMALFAP
INHBABGN
CELL CYCLEKi-67
c-MYCMYBL2
REFERENCEATP5EGPX1PGK1UBB
VDAC2
GADD45B
RECURRENCE SCORECalculated from Tumor
Gene Expression
Prospectively-Defined Primary Analysis in Stage II Colon Cancer (n=711)
Group Risk (by Kaplan-Meier) 12% 18% 22%
![Page 20: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/20.jpg)
QUASAR RESULTS: Recurrence Score, T Stage, and MMR Deficiency are Key Independent Predictors of Recurrence in Stage II Colon Cancer
Multivariate Analysis
![Page 21: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/21.jpg)
QUASAR Results: Recurrence Risk in Pre-specified Recurrence Risk Groups
Comparison of High vs. Low Recurrence Risk Groups using Cox Model: HR = 1.47 (p=0.046)
Recurrence Risk Group
Range of RS
Proportion of patients
Low <30 43.7%
Intermediate 30-40 30.7%
High ≥41 25.6%
22% (16%-29%)
18% (13%-24%)
12% ( 9% -16%)
Kaplan-Meier Estimates (95% CI) of Recurrence Risk at 3 years
Years
Recurrence Risk Group
High
Intermediate
Low
Pro
port
ion
Eve
nt F
ree
0.0
0.2
0.4
0.6
0.8
1.0
0 1 2 3 4 5
n=711Kerr et al., ASCO 2009, #4000
![Page 22: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/22.jpg)
Relationship between the continuous Recurrence Score (RS) and 5-year recurrence risk by stage and treatment in
National Surgical Adjuvant Breast and Bowel Project C-07.
Yothers G et al. JCO 2013;31:4512-4519©2013 by American Society of Clinical Oncology
![Page 23: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/23.jpg)
Recurrence-free interval for (A) all patients and (B) stage II, (C) stage IIIA/B, and (D) stage IIIC patients by Recurrence Score (RS) groups and treatment in National Surgical Adjuvant
Breast and Bowel Project C-07.
Yothers G et al. JCO 2013;31:4512-4519
©2013 by American Society of Clinical Oncology
![Page 24: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/24.jpg)
Overall Survival by Treatment, Stage II dMMR patients
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8Years
% A
live
HR: 3.15 (1.07-9.29)p=0.03
N = 55
N = 47
Untreated 93%Treated 75%
5 yr OS
P-value = 0.014 for treatment by MMR status interaction
![Page 25: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/25.jpg)
Kaplan–Meier estimates of disease-free survival (DFS) in the groups of patients given 5-fluorouracil and leucovorin (FL) or FOLFOX according to tumour p53 expression and
microsatellite instability (MSI) phenotype.
Zaanan A et al. Ann Oncol 2009;21:772-780
© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected]
![Page 26: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/26.jpg)
REMARK diagram of mutation profiling of NSABP trials C-07 and C-08.
Gavin P G et al. Clin Cancer Res 2012;18:6531-6541
©2012 by American Association for Cancer Research
![Page 27: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/27.jpg)
Overlap of mutations in the BRAF, KRAS, NRAS, and PIK3CA are shown.
Gavin P G et al. Clin Cancer Res 2012;18:6531-6541
©2012 by American Association for Cancer Research
![Page 28: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/28.jpg)
Kaplan–Meier plots of BRAF and MMR status cases.
Gavin P G et al. Clin Cancer Res 2012;18:6531-6541
©2012 by American Association for Cancer Research
![Page 29: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/29.jpg)
Kaplan–Meier survival plots for colorectal cancer according to combined MSI/BRAF subgroup.
Lochhead P et al. JNCI J Natl Cancer Inst 2013;105:1151-1156
© The Author 2013. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: [email protected].
![Page 30: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/30.jpg)
The phosphatidylinositol 3-kinase (PI3K) signaling pathway and its potential interaction with the influence of aspirin on colorectal
cancer (CRC) and the tumor microenvironment.
Fuchs C S , and Ogino S JCO 2013;31:4358-4361
©2013 by American Society of Clinical Oncology
![Page 31: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/31.jpg)
Mortality among Patients with Colorectal Cancer, According to Regular Use or Nonuse of Aspirin after Diagnosis and PIK3CA
Mutation Status.
Liao X et al. N Engl J Med 2012;367:1596-1606
![Page 32: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/32.jpg)
Biomarkers Indicating Aspirin Efficiency
COX - 2 over expressing tumors
PIK3CA - mutant tumors
BRAF - wild type tumors
Nurses’ Health and Health Professional follow-up studyFrom Tougeron et. al. Clin Cancer Res 2013
![Page 33: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/33.jpg)
Colorectal Cancer: Diet and Lifestyle Impact on Cancer Patients
Many studies on diet / lifestyle and risk of DEVELOPING colorectal cancer
Few studies show whether these factors affect patients with colorectal cancerDisease recurrenceSurvivalTolerance to chemotherapy
![Page 34: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/34.jpg)
Forest plots of hazard ratios (black divided by white) for death (overall survival [OS]), recurrence or death (recurrence-free survival [RFS]), and recurrence
(recurrence-free interval [RFI]).
Yothers G et al. JNCI J Natl Cancer Inst 2011;103:1498-1506
© The Author 2011. Published by Oxford University Press.
![Page 35: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/35.jpg)
Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy
CancerVolume 119, Issue 8, pages 1528-1536, 10 JAN 2013 DOI: 10.1002/cncr.27938http://onlinelibrary.wiley.com/doi/10.1002/cncr.27938/full#fig1
![Page 36: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/36.jpg)
CALGB 89803: DFS By Dietary Pattern
11 1.1 10.7
1.3
0
0.5
1
1.5
2
2.5
3
3.5
4
1 2 3 4 5Quintiles of Dietary Pattern
Haz
ard
Ratio
for C
ance
r Rec
urre
nce
or D
eath
Prudent diet
1.2
22.2
3.9
Western diet
P, trend < 0.001P, trend < 0.001
Meyerhardt, J. et al. JAMA 2007298(7):754-764.
![Page 37: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/37.jpg)
Plasma Vitamin D and Survival in Colorectal Cancer Patients: NHS/HPFS (N = 304)
1
0.890.83
0.49
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
<22.8 22.8-27.1 27.2-33.1 >33.1
Quintiles of plasma Vitamin D ng/mL
Haz
ard
Ratio
for D
eath
(0.28-0.86)
P, trend = 0.01
People with highest level of vitamin D have 50% improvement in outcome
Ng et al J Clin Oncol. 2008 Jun 20;26(18):2984-91
![Page 38: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/38.jpg)
Clinical potential of prognostic gene expression–based tests for colon cancer stage II and III. According to standard protocols, adjuvant treatment of patients
with colon cancer stage II and III is decided by assessment of risk of relapse after surgical res...
Sveen A et al. Clin Cancer Res 2013;19:6669-6677
©2013 by American Association for Cancer Research
![Page 39: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/39.jpg)
E5202 Trial Schema
Low-Risk PatientsMSS or MSI-L with
retention of 18q allelesMSI-H
Arm A:mFOLFOX6q2w × 12
Arm B:mFOLFOX6 + bevacizumab* q2w × 12
Arm C:Observation only
High-Risk PatientsMSS/18q LOH orMSI-L/18q LOH
areRANDOMIZED
MSI-L = low-level microsatellite instabilityMSI-H = high-level microsatellite instability*Bevacizumab continued for an additional 6 months
Stratify:Disease stage
(IIA or IIB)Microsatellite stability
(stable vs MSI)18q LOH
![Page 40: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/40.jpg)
Stage II CRC Treatment Summary:
Discuss risks with patients including potential link between risk
and lifestyle factors and race
MSI testing for Stage II patients
Acknowledge risk is not associated with treatment efficiency (T3
MSS)
![Page 41: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/41.jpg)
Stage II CRC Treatment Summary:
5FU/capecitabine remains an appropriate consideration
(T3 MSS, elderly)
Discuss lifestyle changes = diet, exercise
MSI-H T3 – no treatment
Oxaliplatin + 5FU/capecitabine (T4b MSI-H and high risk, MSS
BRAF mutated)
Role of ASA for patients with mutated – PIK3CA evolving
![Page 42: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/42.jpg)
![Page 43: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/43.jpg)
Observed Survival Rates for 28,491 Cases with Adenocarcinoma of the Colon
Reproduced with permission from Springer.Edge SB, et al (eds.) AJCC Cancer Staging Manual and Handbook,
7th edition. New York, NY: Springer; 2009.
![Page 44: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/44.jpg)
Recurrence-free interval by stage and treatment in National Surgical Adjuvant Breast and Bowel Project C-07.
Yothers G et al. JCO 2013;31:4512-4519
©2013 by American Society of Clinical Oncology
![Page 45: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/45.jpg)
Rates of (A) disease-free, (B) relapse-free, (C) overall, and (D) post–disease-free survival in patients older than 70 years treated with leucovorin and fluorouracil with oxaliplatin
(FOLFOX4) or without (FL).
Tournigand C et al. JCO 2012;30:3353-3360
©2012 by American Society of Clinical Oncology
![Page 46: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/46.jpg)
K-M plot of recurrence-free survival in C-07 according to treatment and MMR status.
Gavin P G et al. Clin Cancer Res 2013;19:1301
©2013 by American Association for Cancer Research
![Page 47: Al B. Benson III, MD, FACP Professor of Medicine Associate Director for Clinical Investigations Robert H. Lurie Comprehensive Cancer Center of Northwestern](https://reader037.vdocuments.net/reader037/viewer/2022110101/56649eb45503460f94bbb872/html5/thumbnails/47.jpg)
The effect of bevacizumab (Bev) treatment on overall survival by mismatch repair (MMR) status for colon cancer: NSABP C-08.
Pogue-Geile K et al. JNCI J Natl Cancer Inst 2013;105:989-992
© The Author 2013. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: [email protected].